Expect a sharp decline in NMRA shares on this news as the company's most advanced program has failed. The stock may find some support from the extended cash runway and remaining pipeline, but the lack of a late-stage asset makes the company a high-risk binary story. Monitor for potential strategic alternatives (partnerships, licensing, or M&A) as the board evaluates options. Short-term volatility likely elevated.
Price Chart
Executive Summary
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder failed to achieve statistical significance on the primary endpoint, leading to discontinuation of its lead pipeline asset. The company is implementing a 35% workforce reduction to generate ~$10M in annualized savings, incurring ~$2M in restructuring costs, and amended its loan agreement to extend the interest-only period and adjust liquidity covenants. Cash runway is extended into Q3 2027, but the loss of the most advanced program is a severe setback for this clinical-stage biotech.
Key Facts
- Phase 3 KOASTAL-2 (n=430) and KOASTAL-3 (n=422) both failed primary endpoint (MADRS change from baseline at week 6); p-values 0.813 and 0.480 respectively
- Navacaprant development discontinued entirely
- Workforce reduction of approximately 35% implemented on June 12, 2026
- Expected annualized cost savings of ~$10 million from the reduction in force
- One-time restructuring costs of ~$2 million to be incurred in Q2 2026
- Third Amendment to Loan and Security Agreement with K2 HealthVentures extended interest-only period and modified minimum liquidity covenant (effective July 1, 2026)
- Cash and cash equivalents expected to provide runway into Q3 2027
- Pipeline now consists of early-stage programs: NMRA-511 (Alzheimer's agitation, Phase 2b planned by end 2026), NMRA-898 (schizophrenia, Phase 1 data H2 2026), NMRA-215 (obesity, clinical studies by year end 2026)
Financial Impact
Loss of lead pipeline asset eliminates near-term revenue potential; restructuring saves ~$10M annually but signals severe pipeline setback; cash runway extended to Q3 2027 provides ~12-15 months of operating buffer
Risk Factors
- Further pipeline failures in remaining early-stage programs (NMRA-511, NMRA-898, NMRA-215)
- Inability to attract partnership or financing given depleted pipeline
- Potential need for additional dilutive capital if cash runway proves insufficient
- Liquidity covenant under amended loan agreement may constrain operations if milestones not met
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-270328 |
| Document: d943192dex991.htm | 0001193125-26-270328 |
| Document: 0001193125-26-270328-index-headers.html | 0001193125-26-270328 |
| Document: 0001193125-26-270328-index.html | 0001193125-26-270328 |
| Document: 0001193125-26-270328.txt | 0001193125-26-270328 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | 144 | $1.63 $0.6918 | ▲ +57.56% | ▲ +57.03% | $0.4999 (+69.33%) |
Aug 17, 2026 6w ago | 144 | $1.64 $0.7732 | ▲ +52.85% | ▲ +51.54% | $0.4999 (+69.52%) |
Aug 14, 2026 7w ago | 8-K | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Aug 14, 2026 7w ago | Press Release | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Jul 27, 2026 9w ago | 8-K | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jul 27, 2026 9w ago | Press Release | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jun 15, 2026 15w ago | 8-K | $0.9145 $1.60 | ▼ −74.96% | ▼ −75.71% | $0.4999 (+45.34%) |
Apr 17, 2026 24w ago | DEFA14A | $2.19 $1.77 | ▼ −19.18% | ▼ −23.38% | $0.4999 (−77.17%) |
Mar 30, 2026 26w ago | Press Release | $1.93 $2.25 | ▲ +16.58% | ▲ +3.98% | $0.4999 (−74.10%) |
Mar 16, 2026 28w ago | Press Release | $2.87 $2.03 | ▼ −29.27% | ▼ −33.05% | $0.4999 (−82.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access